

Status: Currently Official on 16-Feb-2025
Official Date: Official Prior to 2013
Document Type: Reagents
DocId: GUID-05EF1B06-3E41-422C-9CB2-300A63F1EB09_1_en-US
DOI: https://doi.org/10.31003/USPNF_R2347_01_01
DOI Ref: 4111p

© 2025 USPC
Do not distribute

Potassium Hyaluronate

—White to cream-colored powder. Freely soluble in water. Store in a tight container, in a refrigerator.

Inhibitor Content: Prepare as directed in the Assay under [Hyaluronidase for Injection](#) (USP monograph) a quantity of *Standard solution* containing 1 USP Hyaluronidase Unit in each mL, and a similar quantity of acetate-buffered *Standard solution* using as the solvent 0.1 M, pH 6 sodium acetate buffer (prepared by diluting the 0.2 M buffer prepared as directed below with an equal volume of water). Prepare from the potassium hyaluronate under test 10 mL of *Potassium hyaluronate stock solution*, and dilute 2 mL of it with the specified *Phosphate buffer solution* to make a *Hyaluronate solution*. In the same way, and concurrently, dilute a second 2-mL portion of the stock solution with 0.2 M, pH 6 sodium acetate buffer (containing 16.4 g of anhydrous sodium acetate and 0.45 mL of glacial acetic acid in each 1000 mL).

Place 0.50-mL portions of the *Hyaluronate solution* in each of four 16- × 100-mm test tubes, and place 0.50-mL portions of the acetate-buffered *Hyaluronate solution* in two similar tubes. To two of the four tubes containing *Hyaluronate solution* add 0.50 mL of *Diluent for hyaluronidase solutions*, prepared as directed in the Assay under [Hyaluronidase for Injection](#) (USP monograph). To the remaining two tubes, on a rigid schedule, at 30-second intervals, add 0.50 mL of *Standard solution*. Similarly, to the two tubes containing acetate-buffered *Hyaluronate solution* add at 30-second intervals 0.50-mL portions of acetate-buffered *Standard solution*. Then proceed as directed in the second paragraph for *Procedure*, beginning with “Mix the contents,” as far as “Plot the average.” The reduction in absorbance of acetate-buffered *Hyaluronate solution* is not less than 25% of that observed in the *Hyaluronate solution*.

Turbidity production: The average absorbance of the solutions in the two tubes containing *Hyaluronate solution* and *Diluent for hyaluronidase solutions* prepared in the test for *Inhibitor Content* is not less than 0.26 at a wavelength of 640 nm in a suitable spectrophotometer using a 1-cm cell.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
POTASSIUM HYALURONATE	Margareth R.C. Marques Principal Scientific Liaison	HDQ Headquarters

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: [GUID-05EF1B06-3E41-422C-9CB2-300A63F1EB09_1_en-US](#)

DOI: https://doi.org/10.31003/USPNF_R2347_01_01

DOI ref: [4111p](#)